Lonza Integrates New Serialization Security Capabilities

Lonza’s integrated development and manufacturing site for biopharmaceutical liquid-filled hard capsules has new anti-counterfeiting security capabilities in place and is now in full compliance with EU and U.S. regulatory requirements for serialization.

With increasing threats to patient safety from counterfeited and diverted pharmaceuticals, new rules for serialization in more than 40 countries are being implemented to secure the world’s pharmaceutical supply chain.

To read the full article, click here.